CDK5R2

Across TCGA pan-cancer cohorts, CDK5R2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CDK5R2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CDK5R2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK5R2 expression acts as an unfavorable survival marker.

OV and UCEC are the cancer types where CDK5R2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CDK5R2–OV (DFS)

Open the OV breakdown →